Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Drugs using inhibitors of mammalian target of rapamycin provide a real opportunity to treat patients with much lower exposure to calcineurin inhibitors. Long-term studies remain to be completed that show whether this might lead to important reductions in drug-related kidney damage. Evidence is starting to accumulate that the use of a mammalian target of rapamycin inhibitor early after transplantation might be contraindicated because of impairment in tubular regeneration. © 2004 Lippincott Williams & Wilkins.

Original publication

DOI

10.1097/01.mot.0000146560.58398.e4

Type

Journal article

Journal

Current Opinion in Organ Transplantation

Publication Date

01/12/2004

Volume

9

Pages

361 - 368